ESPR’s Nexletol—(bempedoic acid)—had only a modest effect size on MACE endpoints in a large outcomes study that read out in Mar 2023 (#msg-171369854).
Based on that trial, ESPR’s partner, Daiichi Sankyo is pulling out of the partnership and is refusing to pay ESPR a $300M milestone that was based on the clinical data (#msg-171455404).
Re; bempedoic acid, have no confirming link but one party "said" to me their doctor claimed it was too weak to reduce cholesterol level for that patient.
I was recently prescribed Nexlizet which is a combination of bempedoic acid and zetia. Did a good job on cholesterol but coundn't sleep past 4 AM. About $400 month.
News 
Market Data 
Discover 
